The company has significantly boosted its progress of the novel treatment for cardiac amyloidosis, employing the compound. Initial clinical results suggests potential outcomes for those affected by the serious disease. https://biotech617949.idblogz.com/42469069/bridgebio-advances-attr-cm-management-through-the-drug